
AlgometRx offers innovative pain assessment and analgesic technology through pupil analysis and neuroselective stimulation.
AlgometRx was founded with the mission to revolutionize pain assessment and analgesic prescribing through innovative technology. The company's core product, the AlgometRx Nociometer®, utilizes advanced algorithms to analyze pupil dilation in response to neuroselective stimulation, creating a detailed nociceptive profile. This profile helps to accurately characterize pain type and intensity, as well as assess the pharmacodynamic impact of analgesics. AlgometRx aims to bring objectivity and precision to pain management across various populations.
Notable figures associated with AlgometRx include experts in pain management and technology innovation, though specific names are not provided. The company has achieved significant milestones by developing a transformative platform that shifts the paradigm in pain assessment. Their technology has the potential to greatly impact clinical practices, improving patient outcomes through more accurate and personalized pain management strategies.

PainQx
painqx.com

Doloromics
doloromics.com

XpressiveTech
xpressivetech.com

Concentric Analgesics

Vapogenix
vapogenix.com

Amalgent Therapeutics
amalgent.com

Allay Therapeutics
allaytx.com

NeuroMetrix
neurometrix.com

PainNavigator
navigatemypain.com

Alleviate

Neurocarrus
neurocarrus.com

Prohuman Technologies

Thermaquil
thermaquil.com

NeuraLace Medical

JointMetrix Medical
Companies similar to AlgometRx include PainQx, Doloromics, XpressiveTech and Concentric Analgesics.
AlgometRx was founded in 2015.
AlgometRx's headquarters is located in Washington, D.C., DC, US.
AlgometRx's most recent funding round was for $50k (USD) in November 2017.
As of Nov 17, 2017, AlgometRx has raised a total of $1.1M (USD).
AlgometRx has 5 employees as of Feb 5, 2024.